Nature Genetics, ISSN 1061-4036, 01/2009, Volume 41, Issue 10, pp. 1116 - 21
Prostate cancer (PrCa) is the most frequently diagnosed cancer in males in developed countries. To identify common PrCa susceptibility alleles, we previously...
RISK | AUSTRALIAN CASE-CONTROL | VARIANTS | MULTIPLE | GENETICS & HEREDITY | ANTIGEN | Genome-Wide Association Study | Disease Susceptibility | Prostatic Neoplasms - genetics | Humans | Genotype | Male | Chromosomes, Human | Polymorphism, Single Nucleotide | Genome, Human | Disease susceptibility | Genetic aspects | Research | Diagnosis | Single nucleotide polymorphisms | Health aspects | Prostate cancer | Risk factors | Studies | Medical research | Inflation | Regression analysis | Chromosomes
RISK | AUSTRALIAN CASE-CONTROL | VARIANTS | MULTIPLE | GENETICS & HEREDITY | ANTIGEN | Genome-Wide Association Study | Disease Susceptibility | Prostatic Neoplasms - genetics | Humans | Genotype | Male | Chromosomes, Human | Polymorphism, Single Nucleotide | Genome, Human | Disease susceptibility | Genetic aspects | Research | Diagnosis | Single nucleotide polymorphisms | Health aspects | Prostate cancer | Risk factors | Studies | Medical research | Inflation | Regression analysis | Chromosomes
Journal Article
Prostate Cancer and Prostatic Diseases, ISSN 1365-7852, 2009, Volume 12, Issue 2, pp. 192 - 197
The fibroblast growth factor receptor 4 (FGFR4) is thought to be involved in many critical cellular processes and has been associated with prostate cancer...
population-based association analysis | ADENOCARCINOMA | RECEPTOR | INTRAEPITHELIAL NEOPLASIA | ARG ALLELE | BREAST-CANCER | radical prostatectomy | THERAPY | ONCOLOGY | GROWTH | GLY388ARG POLYMORPHISM | UROLOGY & NEPHROLOGY | OVER-EXPRESSION | FGFR4 | PROGRESSION | Genetic Predisposition to Disease | Prognosis | Prostatic Neoplasms - surgery | Humans | Middle Aged | Risk Factors | Male | Case-Control Studies | Prostatic Neoplasms - genetics | Adult | Prostatectomy | Adenocarcinoma - genetics | Aged | Biomarkers, Tumor - genetics | Polymorphism, Single Nucleotide | Receptor, Fibroblast Growth Factor, Type 4 - genetics | Adenocarcinoma - surgery | Physiological aspects | Genetic aspects | Growth factor receptors | Research | Health aspects | Prostate cancer | Genetic polymorphisms | Risk factors | prostate cancer | population based association analysis
population-based association analysis | ADENOCARCINOMA | RECEPTOR | INTRAEPITHELIAL NEOPLASIA | ARG ALLELE | BREAST-CANCER | radical prostatectomy | THERAPY | ONCOLOGY | GROWTH | GLY388ARG POLYMORPHISM | UROLOGY & NEPHROLOGY | OVER-EXPRESSION | FGFR4 | PROGRESSION | Genetic Predisposition to Disease | Prognosis | Prostatic Neoplasms - surgery | Humans | Middle Aged | Risk Factors | Male | Case-Control Studies | Prostatic Neoplasms - genetics | Adult | Prostatectomy | Adenocarcinoma - genetics | Aged | Biomarkers, Tumor - genetics | Polymorphism, Single Nucleotide | Receptor, Fibroblast Growth Factor, Type 4 - genetics | Adenocarcinoma - surgery | Physiological aspects | Genetic aspects | Growth factor receptors | Research | Health aspects | Prostate cancer | Genetic polymorphisms | Risk factors | prostate cancer | population based association analysis
Journal Article
3.
Full Text
Compensatory smoking from gradual and immediate reduction in cigarette nicotine content
Cancer Epidemiology Biomarkers and Prevention, ISSN 1055-9965, 02/2015, Volume 24, Issue 2, pp. 472 - 476
Reducing the addictiveness of cigarettes by reducing their nicotine content can potentially have a profound impact on public health. Two different approaches...
ONCOLOGY | PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH | EXPOSURE | Nicotine - administration & dosage | Dangerous Behavior | Humans | Middle Aged | Male | Young Adult | Cotinine - blood | Tobacco Use Cessation Products | Nicotine - chemistry | Adult | Female | Smoking - psychology | Cotinine - urine | nicotine exposure | smoking behavior | reduced nicotine cigarettes-compensatory smoking | gradual vs. immediate reduction
ONCOLOGY | PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH | EXPOSURE | Nicotine - administration & dosage | Dangerous Behavior | Humans | Middle Aged | Male | Young Adult | Cotinine - blood | Tobacco Use Cessation Products | Nicotine - chemistry | Adult | Female | Smoking - psychology | Cotinine - urine | nicotine exposure | smoking behavior | reduced nicotine cigarettes-compensatory smoking | gradual vs. immediate reduction
Journal Article
CANCER PREVENTION RESEARCH, ISSN 1940-6207, 03/2019, Volume 12, Issue 3, pp. 171 - 183
The best known ovarian cancer biomarker, CA125, is neither adequately sensitive nor specific for screening the general population. By using a combination of...
MESOTHELIN | PROSTATE | CYTOKINES | TUMOR-MARKERS | ONCOLOGY | EPIDERMAL-GROWTH-FACTOR | RISK | AUTOANTIBODY | EXPRESSION | CARCINOMA | COLLABORATIVE TRIAL
MESOTHELIN | PROSTATE | CYTOKINES | TUMOR-MARKERS | ONCOLOGY | EPIDERMAL-GROWTH-FACTOR | RISK | AUTOANTIBODY | EXPRESSION | CARCINOMA | COLLABORATIVE TRIAL
Journal Article
Molecular Cancer Therapeutics, ISSN 1535-7163, 05/2017, Volume 16, Issue 5, pp. 956 - 965
Sarcomas differ from carcinomas in their mesenchymal origin. Therapeutic advancements have come slowly, so alternative drugs and models are urgently needed....
CANINE HEMANGIOSARCOMA | SYNOVIAL SARCOMA | RECOMBINANT IMMUNOTOXIN | SOFT-TISSUE SARCOMAS | ONCOLOGY | UROKINASE PLASMINOGEN-ACTIVATOR | EPIDERMAL-GROWTH-FACTOR | SPLENIC HEMANGIOSARCOMA | PHASE-I | PSEUDOMONAS EXOTOXIN | LIGAND-DIRECTED TOXIN | Virulence Factors - genetics | Humans | ErbB Receptors - genetics | Hemangiosarcoma - genetics | Molecular Targeted Therapy | ADP Ribose Transferases - administration & dosage | Exotoxins - administration & dosage | Epidermal Growth Factor - chemistry | Bacterial Toxins - genetics | Urokinase-Type Plasminogen Activator - chemistry | ADP Ribose Transferases - chemistry | Disease Models, Animal | Doxorubicin - administration & dosage | Hemangiosarcoma - pathology | ErbB Receptors - antagonists & inhibitors | Exotoxins - chemistry | Epidermal Growth Factor - genetics | Hemangiosarcoma - drug therapy | Virulence Factors - chemistry | Urokinase-Type Plasminogen Activator - genetics | Bacterial Toxins - chemistry | Receptors, Urokinase Plasminogen Activator - antagonists & inhibitors | ADP Ribose Transferases - genetics | Animals | Dogs | Exotoxins - genetics | Cell Line, Tumor | Bacterial Toxins - administration & dosage | Mice | Receptors, Urokinase Plasminogen Activator - genetics | Neoplasm Staging | Virulence Factors - administration & dosage | Spleen | Drugs | Animal models | Carcinoma | Sarcoma | Epidermal growth factor receptors | Mesenchyme | Toxicity | Minimal residual disease | Doxorubicin | Biological activity | U-Plasminogen activator | Urokinase | Epidermal growth factor | Life span | Data collection | Biocompatibility | In vivo methods and tests | Drug dosages | targeted toxin | canine | sarcoma | epidermal growth factor receptor | adaptive clinical trial | urokinase plasminogen activator receptor | Clinical Medicine | Medical and Health Sciences | Cancer and Oncology | Klinisk medicin | Medicin och hälsovetenskap | Cancer och onkologi
CANINE HEMANGIOSARCOMA | SYNOVIAL SARCOMA | RECOMBINANT IMMUNOTOXIN | SOFT-TISSUE SARCOMAS | ONCOLOGY | UROKINASE PLASMINOGEN-ACTIVATOR | EPIDERMAL-GROWTH-FACTOR | SPLENIC HEMANGIOSARCOMA | PHASE-I | PSEUDOMONAS EXOTOXIN | LIGAND-DIRECTED TOXIN | Virulence Factors - genetics | Humans | ErbB Receptors - genetics | Hemangiosarcoma - genetics | Molecular Targeted Therapy | ADP Ribose Transferases - administration & dosage | Exotoxins - administration & dosage | Epidermal Growth Factor - chemistry | Bacterial Toxins - genetics | Urokinase-Type Plasminogen Activator - chemistry | ADP Ribose Transferases - chemistry | Disease Models, Animal | Doxorubicin - administration & dosage | Hemangiosarcoma - pathology | ErbB Receptors - antagonists & inhibitors | Exotoxins - chemistry | Epidermal Growth Factor - genetics | Hemangiosarcoma - drug therapy | Virulence Factors - chemistry | Urokinase-Type Plasminogen Activator - genetics | Bacterial Toxins - chemistry | Receptors, Urokinase Plasminogen Activator - antagonists & inhibitors | ADP Ribose Transferases - genetics | Animals | Dogs | Exotoxins - genetics | Cell Line, Tumor | Bacterial Toxins - administration & dosage | Mice | Receptors, Urokinase Plasminogen Activator - genetics | Neoplasm Staging | Virulence Factors - administration & dosage | Spleen | Drugs | Animal models | Carcinoma | Sarcoma | Epidermal growth factor receptors | Mesenchyme | Toxicity | Minimal residual disease | Doxorubicin | Biological activity | U-Plasminogen activator | Urokinase | Epidermal growth factor | Life span | Data collection | Biocompatibility | In vivo methods and tests | Drug dosages | targeted toxin | canine | sarcoma | epidermal growth factor receptor | adaptive clinical trial | urokinase plasminogen activator receptor | Clinical Medicine | Medical and Health Sciences | Cancer and Oncology | Klinisk medicin | Medicin och hälsovetenskap | Cancer och onkologi
Journal Article
No results were found for your search.
Cannot display more than 1000 results, please narrow the terms of your search.